NASDAQ:ALQA - Alliqua Biomedical Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Alliqua Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALQA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALQA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Alliqua Biomedical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ALQA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Alliqua Biomedical. This rating has held steady since January 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2019HC WainwrightReiterated RatingNeutralLow
1/8/2018HC WainwrightDowngradeBuy ➝ Neutral$4.50 ➝ $2.80High
1/3/2018HC WainwrightSet Price TargetBuy$5.00High
9/18/2017HC WainwrightReiterated RatingBuy$15.00Low
8/11/2017HC WainwrightSet Price TargetBuy$20.00High
7/4/2017HC WainwrightLower Price TargetBuy$25.00 ➝ $15.00Low
5/11/2017HC WainwrightSet Price TargetBuy$20.00Low
4/11/2017CowenReiterated RatingOutperform$15.00Low
4/7/2017HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $15.00Medium
3/8/2017Chardan CapitalLower Price TargetBuy ➝ Buy$20.00 ➝ $12.50High
(Data available from 11/28/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Alliqua Biomedical logo
Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $2.81
Low: $2.20
High: $3.23

52 Week Range

Now: N/A

Volume

371,516 shs

Average Volume

114,400 shs

Market Capitalization

$13.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Alliqua Biomedical?

The following sell-side analysts have issued reports on Alliqua Biomedical in the last year:
View the latest analyst ratings for ALQA.

What is the current price target for Alliqua Biomedical?

0 Wall Street analysts have set twelve-month price targets for Alliqua Biomedical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Alliqua Biomedical in the next year.
View the latest price targets for ALQA.

What is the current consensus analyst rating for Alliqua Biomedical?

Alliqua Biomedical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALQA.

What other companies compete with Alliqua Biomedical?

How do I contact Alliqua Biomedical's investor relations team?

Alliqua Biomedical's physical mailing address is 2150 CABOT BLVD WEST SUITE B, LANGHORNE PA, 19047. The company's listed phone number is 215-702-8550 and its investor relations email address is [email protected] The official website for Alliqua Biomedical is www.alliqua.com.